Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-11-29T11:28:21.506Z Has data issue: false hasContentIssue false
  • English
  • Français

Is there a role of adjuvant treatment for salivary duct carcinoma?

Published online by Cambridge University Press:  23 February 2015

T Nakashima ,
R Yasumatsu ,
S Toh ,
K Hashimoto ,
M Shinoto ,
K Nakamura  and
S Komune
T Nakashima*
Affiliation:
Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
R Yasumatsu
Affiliation:
Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
S Toh
Affiliation:
Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
K Hashimoto
Affiliation:
Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
M Shinoto
Affiliation:
Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
K Nakamura
Affiliation:
Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
S Komune
Affiliation:
Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
*
Address for correspondence: T Nakashima, Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

To determine the clinical effect of post-operative radiotheraphy and systemic chemotherapy for the treatment of salivary duct carcinoma.

Study design:

Retrospective review.

Design:

The medical records of 26 patients treated by surgery with or without radiotheraphy and/or systemic chemotherapy for salivary duct carcinoma were retrospectively reviewed to investigate the role of post-operative adjuvant treatment for the patients' prognosis.

Results:

The overall three-year and five-year survival rates were 54 and 48.1 per cent, respectively. There was no correlation with the clinical stage and the patients' prognosis. The overall three-year survival of the patients with or without post-operative radiotheraphy was 64 and 33 per cent, respectively (p = 0.29). The overall three-year survival of the patients with or without post-operative chemotherapy was 53 and 56 per cent, respectively (p = 0.78).

Conclusion:

Post-operative adjuvant therapy did not improve the patients' overall prognosis with salivary duct carcinoma. Developing novel treatment modalities may be necessary to improve the prognosis of this aggressive disease.

Keywords

Salivary duct carcinomaRTChemotherapyAdjuvant treatment
Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 129 , Issue S2 , March 2015 , pp. S98 - S101
Copyright
Copyright © JLO (1984) Limited 2015 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Guzzo, M, Di Palma, S, Grandi, C, Molinari, R. Salivary duct carcinoma: clinical characteristics and treatment strategies. Head Neck 1997;19:126–333.0.CO;2-6>CrossRefGoogle ScholarPubMed
2Barnes, L, Rao, U, Krause, J, Contis, L, Schwartz, A, Scalamogna, P. Salivary duct carcinoma. Part I. A clinicopathologic evaluation and DNA image analysis of 13 cases with review of the literature. Oral Surg Oral Med Oral Pathol 1994;78:64–73Google Scholar
3Jayaprakash, V, Merzianu, M, Warren, GW, Arshad, H, Hicks, WL Jr, Rigual, NR et al. Survival rates and prognostic factors for infiltrating salivary duct carcinoma: analysis of 228 cases from the Surveillance, Epidemiology, and End Results database. Head Neck 2014;36:694–701Google Scholar
4Shinoto, M, Shioyama, Y, Nakamura, K, Nakashima, T, Kunitake, N, Higaki, Y et al. Postoperative radiotherapy in patients with salivary duct carcinoma: clinical outcomes and prognostic factors. J Radiat Res 2013;54:925–30Google Scholar
5Kim, JY, Lee, S, Cho, KJ, Kim, SY, Nam, SY, Choi, SH et al. Treatment results of post-operative radiotherapy in patients with salivary duct carcinoma of the major salivary glands. Br J Radiol 2012;85:e947–52Google Scholar
6Dimery, IW, Legha, SS, Shirinian, M, Hong, WK. Fluorouracil, doxorubicin, cyclophosphamide, and cisplatin combination chemotherapy in advanced or recurrent salivary gland carcinoma. J Clin Oncol 1990;8:1056–62Google Scholar
7Dodd, RL, Slevin, NJ. Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies. Oral Oncol 2006;42:759–69Google Scholar
8Lewis, JE, McKinney, BC, Weiland, LH , Ferreiro, JA , Olsen, KDSalivary duct carcinoma. Clinicopathologic and immunohistochemical review of 26 cases. Cancer 1996;77:223–30Google Scholar
9Krishnamurthy, J, Krishnamurty, DM, Baker, JJ, Zhen, W, Lydiatt, D, Ganti, AKSalivary duct carcinoma responding to trastuzumab-based therapy: case report and review of the literature. Head Neck 2013;35:E372–5Google Scholar
10Jaspers, HC, Verbist, BM, Schoffelen, R, Mattijssen, V, Slootweg, PJ, van der Graaf, WT et al. Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options. J Clin Oncol 2011;29:e473–6Google Scholar
11Masubuchi, T, Tada, Y, Maruya, SI, Osamura, Y, Kamata, SE, Miura, K et al. Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma. Int J Clin Oncol 2014; in press.Google ScholarPubMed
12Soper, MS, Iganej, S, Thompson, LD. Definitive treatment of androgen receptor-positive salivary duct carcinoma with androgen deprivation therapy and external beam radiotherapy. Head Neck 2014;36:E4–7Google Scholar